User profiles for Jackie Bosch
 | Jackie Bosch, Jacqueline BoschVerified email at mcmaster.ca Cited by 40434 |
[HTML][HTML] Rivaroxaban with or without aspirin in stable cardiovascular disease
Background We evaluated whether rivaroxaban alone or in combination with aspirin would
be more effective than aspirin alone for secondary cardiovascular prevention. Methods In this …
be more effective than aspirin alone for secondary cardiovascular prevention. Methods In this …
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial
Background: The cardiovascular risk associated with early renal insufficiency is unknown.
Clinicians are often reluctant to use angiotensin-converting enzyme inhibitors in patients with …
Clinicians are often reluctant to use angiotensin-converting enzyme inhibitors in patients with …
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.
Objective To evaluate whether long-term supplementation with vitamin E decreases the risk
of cancer, cancer death, and major cardiovascular events.
of cancer, cancer death, and major cardiovascular events.
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE)
…, CI Doris, Q Yi, S Smith, A Moore-Cox, J Bosch… - Circulation, 2001 - Am Heart Assoc
Background—Activation of the renin-angiotensin-aldosterone system and oxidative modification
of LDL cholesterol play important roles in atherosclerosis. The Study to Evaluate Carotid …
of LDL cholesterol play important roles in atherosclerosis. The Study to Evaluate Carotid …
[HTML][HTML] Cholesterol lowering in intermediate-risk persons without cardiovascular disease
Background Previous trials have shown that the use of statins to lower cholesterol reduces
the risk of cardiovascular events among persons without cardiovascular disease. Those trials …
the risk of cardiovascular events among persons without cardiovascular disease. Those trials …
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
Background Patients with peripheral artery disease have an increased risk of cardiovascular
morbidity and mortality. Antiplatelet agents are widely used to reduce these complications. …
morbidity and mortality. Antiplatelet agents are widely used to reduce these complications. …
[HTML][HTML] Blood-pressure lowering in intermediate-risk persons without cardiovascular disease
Background Antihypertensive therapy reduces the risk of cardiovascular events among high-risk
persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its …
persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its …
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril
Background Electrocardiographic markers of left ventricular hypertrophy (LVH) predict poor
prognosis. We determined whether the ACE inhibitor ramipril prevents the development and …
prognosis. We determined whether the ACE inhibitor ramipril prevents the development and …
Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals
Importance Current guidelines advocate the use of marine-derived omega-3 fatty acids
supplements for the prevention of coronary heart disease and major vascular events in people …
supplements for the prevention of coronary heart disease and major vascular events in people …
Ramipril and the development of diabetes
ContextType 2 diabetes is a growing clinical and public health problem. Preventive efforts
related to lifestyle modification are not always successful; therefore, alternative prevention …
related to lifestyle modification are not always successful; therefore, alternative prevention …